Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Education | $194.99 | 2 | 90.7% |
| Food and Beverage | $20.01 | 1 | 9.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Astellas Pharma US Inc | $99.99 | 1 | $0 (2019) |
| AbbVie, Inc. | $95.00 | 1 | $0 (2019) |
| Incyte Corporation | $20.01 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $20.01 | 1 | Incyte Corporation ($20.01) |
| 2019 | $194.99 | 2 | Astellas Pharma US Inc ($99.99) |
All Payment Transactions
3 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/12/2022 | Incyte Corporation | PEMAZYRE (Drug), MONJUVI, JAKAFI | Food and Beverage | Cash or cash equivalent | $20.01 | General |
| Category: Hepatology (Liver, Pancreatic, Gall Bladder) | ||||||
| 11/14/2019 | AbbVie, Inc. | Venclexta (Drug) | Education | In-kind items and services | $95.00 | General |
| Category: Virology | ||||||
| 09/04/2019 | Astellas Pharma US Inc | — | Education | In-kind items and services | $99.99 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 69 | 4,240 | 92,347 | $8.4M | $2.0M |
| 2022 | 75 | 4,007 | 101,155 | $6.3M | $1.4M |
| 2021 | 30 | 1,035 | 12,571 | $462,260 | $82,100 |
All Medicare Procedures & Services
174 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 33 | 33,400 | $4.9M | $1.4M | 29.3% |
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 11 | 8,920 | $731,880 | $211,735 | 28.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 245 | 682 | $205,855 | $62,968 | 30.6% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 134 | 441 | $368,001 | $44,269 | 12.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 281 | 394 | $71,137 | $24,436 | 34.4% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2023 | 25 | 116 | $114,376 | $21,177 | 18.5% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 38 | 14,690 | $132,210 | $20,066 | 15.2% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 11 | 156 | $225,264 | $13,480 | 6.0% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 21 | 5,380 | $112,980 | $12,846 | 11.4% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 321 | 1,173 | $72,726 | $12,141 | 16.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 70 | 70 | $40,601 | $11,237 | 27.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 332 | 1,319 | $46,165 | $10,038 | 21.7% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 100 | 788 | $82,740 | $9,109 | 11.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 257 | 778 | $14,782 | $6,535 | 44.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 43 | 48 | $24,134 | $6,132 | 25.4% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 17 | 85 | $5,950 | $6,125 | 102.9% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 47 | 116 | $47,226 | $5,717 | 12.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 43 | 43 | $19,807 | $5,573 | 28.1% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 85 | 312 | $24,336 | $5,136 | 21.1% |
| 82607 | Cyanocobalamin (vitamin b-12) level | Office | 2023 | 129 | 306 | $22,644 | $4,523 | 20.0% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 140 | 335 | $19,430 | $4,476 | 23.0% |
| 82746 | Folic acid level, serum | Office | 2023 | 130 | 305 | $21,655 | $4,395 | 20.3% |
| 83520 | Measurement of substance using immunoassay technique | Office | 2023 | 63 | 256 | $46,336 | $4,333 | 9.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 27 | 28 | $10,601 | $3,690 | 34.8% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 24 | 66 | $16,445 | $3,643 | 22.2% |
About Dr. Gradon Nielsen, M.D
Dr. Gradon Nielsen, M.D is a Hematology & Oncology healthcare provider based in Norfolk, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/15/2015. The National Provider Identifier (NPI) number assigned to this provider is 1669868774.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gradon Nielsen, M.D has received a total of $215.00 in payments from pharmaceutical and medical device companies, with $20.01 received in 2022. These payments were reported across 3 transactions from 3 companies. The most common payment nature is "Education" ($194.99).
As a Medicare-enrolled provider, Nielsen has provided services to 9,282 Medicare beneficiaries, totaling 206,073 services with total Medicare billing of $3.5M. Data is available for 3 years (2021–2023), covering 174 distinct procedure/service records.
Practice Information
- Specialty Hematology & Oncology
- Location Norfolk, VA
- Active Since 04/15/2015
- Last Updated 08/05/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1669868774
Products in Payments
- Venclexta (Drug) $95.00
- PEMAZYRE (Drug) $20.01
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Norfolk
Rabih Fahed, M.d, M.D
Hematology & Oncology — Payments: $337,010
Gary Simmons, Do, DO
Hematology & Oncology — Payments: $66,315
Michael Danso, M.d, M.D
Hematology & Oncology — Payments: $54,407
Dr. Shanley Banaag, D.o, D.O
Hematology & Oncology — Payments: $3,419
Thomas Alberico, Md, MD
Hematology & Oncology — Payments: $572.79
Dr. Ranjit Goudar, M.d, M.D
Hematology & Oncology — Payments: $549.21